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Abstract Using a PCR technique, exon # 5 of the human tumor
suppressor gene p53 was amplified and ligated into the pCRII
vector and transformed into Escherichia coli INVKF’ competent
cells. The cloned exon # 5 was 184 bp long. Evidence is presented
to show that after dimethyldioxirane epoxidation, 17L-estradiol
was able to form 17L-estradiol-DNA adducts and to strongly
inhibit the replication of the cloned exon # 5 producing smaller
sizes of DNA fragments and introducing errors of incorporation
at the 3P-end of the terminating DNAs. The errors occurred
mainly at the clusters of the complementary ‘G’ and ‘A’ bases on
the template strand DNA, presumably, the major sites where the
17L-estradiol-DNA adducts were formed.
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1. Introduction
Estrone (E1) and 17L-estradiol (E2) are endogenous female
hormones required for the growth and development in the
target tissues, including the mammary glands. However, ani-
mal and epidemiological studies have clearly indicated that
they are also carcinogenic causing uterine [1,2] and breast
[3^5] cancers. The mechanism of their carcinogenic action is
still largely unknown. Recently, we found that E1 and E2
could be activated by the epoxide-forming oxidant dimethyl-
dioxirane (DMDO), resulting in the inhibition of rat liver
nuclear and nucleolar RNA synthesis in vitro [6]. Since epox-
idation is required for the activation of many well-known
chemical carcinogens, we proposed that epoxidation is the
underlying mechanism for the initiation of estrogen carcino-
genesis [6]. Chemical carcinogenesis is a multistage process
including initiation, promotion and progression [7^9]. Initia-
tion requires the covalent binding of a carcinogen to DNA
[7^9]. Therefore, one of the important tests of our hypothesis
is to determine whether E1 and E2 after DMDO activation are
able to bind to DNA. In support to our hypothesis, we have
found that 3H-labelled E1 and E2 are able to bind to both
G-C and A-T containing DNAs but only after DMDO acti-
vation [10,11]. Additionally, the covalent binding nature of E1
and E2 to DNA after DMDO activation was further con-
¢rmed by 32P-post-labelling analysis using calf thymus as
well as several synthetic DNAs of a known base content
and sequence [10,11]. However, these are in vitro experiments
and it is critical that estrogen-DNA adducts are detected in
vivo. A recent report has shown that when a continuous treat-
ment of E2 was delivered through Silastic tubing implants,
female ACI rats developed 100% mammary tumors [12]. We
found that when the female ACI rats were given intramam-
mallary injection of E2 or DMDO-activated E2, identical
DNA adducts were formed in vivo and that the DMDO-acti-
vated E2 was at least 25 000-fold more active than E2 in the
forming of DNA adducts in the mammary glands [13,14].
P53 is a human tumor suppressor gene [15,16]. Mutation of
p53 is known to be involved in many types of cancers includ-
ing breast cancer [15,17,18]. Exon # 5 of p53 has been iden-
ti¢ed as one of the mutational hotspots in breast cancer pa-
tients [15,17,18]. This work is to report the cloning of exon # 5
of the human tumor suppressor gene p53 and the study of
the e¡ect of E2-DNA adducts on the replication of exon # 5
DNA in vitro.
2. Materials and methods
2.1. Materials
E2 was purchased from Sigma Chemical Company (St. Louis, MO,
USA). A Sequenase Version 2.0 DNA sequencing kit and 5P-
[K-35S]dATP were purchased from Amersham Life Science (Arlingh-
ton Heights, IL, USA). The PHP53B plasmid (ATCC 57254) in Es-
cherichia coli containing the human tumor suppressor gene p53 was
bought from American Type Culture Collection (Rockville, MD,
USA). The QIAprep Plasmid kit was from QIAGEN (Chadsworth,
CA, USA). The p53 exon # 5 sense (5P-TACTCCCCTGCCCTCA-
ACAA-3P) and antisense (5P-CATCGCTATCTGAGCAGCGC-3P)
primers were made by The Great American Gene Company (Ramona,
CA, USA). GeneAmp PCR Reagent kit including Ampli Taq DNA
polymerase was from Perkin Elmer (Branchburg, NJ, USA). TA
Cloning kit Dual Promoter was purchased from Invitrogen (Carlsbad,
CA, USA). The universal SP6 and T7 promoter primers were pur-
chased from Promega (Madison, WI, USA).
2.2. Cloning and sequencing of exon # 5 of the human tumor suppressor
gene p53
The recombinant plasmid PHP53B (ATCC 57254) containing the
pBR322 vector (size 4363 kb) with a 2 kb DNA insert that included
the 135 bp upstream of the ¢rst ATG codon and the entire encoding
sequence of the 393 amino acids of the human tumor suppressor gene
p53 (DNA sequence accession number X02469) in E. coli was incu-
bated in 10 ml L-broth medium containing ampicillin (50 Wg/ml ¢nal
concentration) at 37‡C for 3 h. Then, 200 Wl of these cells was inocu-
lated into a 5 ml fresh L-broth medium containing ampicillin for an
overnight culture at 37‡C with shaking. The cells were then collected
by centrifugation at 3000 rpm for 10 min and lysed. The plasmid
DNA was isolated and puri¢ed using the QIAprep Spin Plasmid kit.
For PCR reaction, 0.5^1.0 Wg of the puri¢ed plasmid DNA was
mixed in a total of 100 Wl of the PCR reaction mixture that contained
10 Wl 10UPCR bu¡er, 200 WM of each dNTPS (¢nal concentration),
1 pM (¢nal concentration) each of the exon # 5 sense and antisense
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primers and 2.5 U Ampli Taq DNA polymerase. The PCR reaction
was carried out at 94‡C for 60 s, 55‡C for 45 s and 72‡C for 90 s, for a
total of 29 cycles. Then, 10 Wl of the PCR product was taken for
agarose (2%) gel electrophoresis to check the size of the ampli¢ed
p53 exon # 5 DNA after ethidium bromide staining and it was vis-
ualized under UV light. For cloning, 1 Wl of the PCR-ampli¢ed p53
exon # 5 DNA was ligated to the pCRII vector (3.9 kb) using T4
DNA ligase at 14‡C for 7 h according to the TA Cloning kit protocol.
The recombinant pCRII vector was transformed into the INVKF’ E.
coli competent cells and the white-colored clones were selected and
incubated in 5 ml L-broth medium containing ampicillin at 37‡C,
overnight with shaking. The recombinant plasmids were puri¢ed
with the QIAprep Plasmid kit. The p53 exon # 5 DNA insertions
were con¢rmed by both PCR and EcoRI double digestion methods.
The sequence of the encoding (sense) strand of the p53 exon # 5 DNA
cloned in pCRII vector replicated from the T7 promoter primer is
shown below:
5P-TACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGC-
CAAGACCTGCCCTGTGCAGCTGTGGGTTGATTCCA-
CACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTA-
CAAGCAGTCACAGCACATGACGGAGGTTGT-
GAGGCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATG-
3P (184 bp).
2.3. Activation of E2 by DMDO
The procedure to activate E2 using the speci¢c epoxide-forming
oxidant DMDO was the same as described previously [6,10,11].
Brie£y, aliquots of 1 ml of the freshly prepared DMDO were mixed
with 1 mg E2 at room temperature for 60 min with gentle shaking.
After activation, the reaction mixture was vacuumed to dryness and
was redissolved in dimethylsulfoxide (DMSO) before use (the E2 ep-
oxide group). In parallel, tubes containing 1 mg E2 were mixed with
1 ml acetone and reacted the same way as DMDO at room temper-
ature for 60 min, then, they were dried. Again, it was dissolved in
DMSO before use (the E2 control group).
2.4. Detection of E2-DNA adducts by 32P-post-labelling
For this study (Fig. 1), three groups of samples were used. (a) The
solvent control group, 5 Wg of the plasmid DNA containing exon # 5
was incubated alone in the presence of 33% DMSO. (b) The E2 con-
trol group, 5 Wg of the plasmid DNA was incubated with 200 Wg E2 in
the presence of 33% DMSO. (c) The E2 epoxide group, 5 Wg of the
plasmid DNA was incubated with 200 Wg of the DMDO-activated E2
in the presence of 33% DMSO. The binding reaction for each group
was carried out at room temperature for 1 h. The nuclease P1-en-
hanced version of the 32P-post-labelling technique was used for DNA
adduct analysis [10,11]. Kodak XAR-5 or Du Pont Cronex 4 X-ray
¢lms and Du Pond Lightning Plus intensifying screens were used for
the detection of DNA adducts after the ¢lms were exposed for 16 h at
380‡C [10,11].
2.5. Assay of DMDO-activated E2 on the replication of exon # 5 DNA
of p53
For the study on the inhibitory e¡ect of E2-DNA adducts on the
replication of exon # 5 DNA of p53 (Table 1), 5 Wg of the pCRII
vector DNA containing exon # 5 of the human tumor suppressor
gene p53 was reacted with 200 Wg of the DMDO-activated E2 for
30 min (30 min group) or for 2 h (2 h group) at room temperature
in a 33% ¢nal concentration of DMSO. For the control, 5 Wg of the
plasmid DNA containing exon # 5 was incubated alone in the pres-
ence of 33% of DMSO for 2 h. The DNA was then denatured in 0.2 M
NaOH (10 min, room temperature) and precipitated with alcohol in
the presence of 3% sodium acetate overnight at 320‡C. The denatured
DNA was annealed with the T7 promoter primer and the replication
was carried out at room temperature for 5 min using the Sequenase
Version 2.0 DNA Sequencing kit according to the conditions speci¢ed
by the protocol (Amersham Life Science, Arlington Heights, IL,
USA), but in the absence of 2P,3P- dideoxynucleoside 5P-triphosphate
(ddNTP) terminators. 5P-[K-35S]dATP was used to monitor the syn-
thesis of DNA. After incubation, 1 Wl aliquots of the reaction mixture
in triplicates were taken from each group for quantitative radioactiv-
ity incorporation determination using TCA washing and GF/C ¢lter
counting as described previously [19,20]. For sequencing gel analysis,
the assay was conducted in the presence of ddNTPs as speci¢ed by the
Sequenase Version 2.0 DNA Sequencing kit. However, the samples
were analyzed in two ways. One was that the samples from each
group containing the same amount of DNA template were applied
to a gel (Fig. 2) and the other was that the samples containing the
same amount of radioactivity were applied to the gel (Fig. 3). DNA
sequencing analysis using an 8% polyacrylamide/7 M urea gel in TBE
bu¡er was performed on a Model S2 Sequencing Gel Electrophoresis
Apparatus (Life Technologies, Gibco BRL Apparatus, Gaithersburg,
MD, USA). The gel was pre-run at 1500 V for 45^60 min. Then, the
samples were applied onto the gel after heat denaturation and electro-
phoresed at 1500 V for an additional 1.5^2 h. After the run, the gel
was vacuum-dried and exposed to the 35U43 Kodak XAR-5 auto-
radiographic ¢lms at room temperature for several days before they
were developed.
3. Results and discussion
Fig. 1 shows the results of the detection of E2-DNA ad-
ducts by 32P-post-labelling analysis using the cloned p53 exon
# 5 DNA. Fig. 1a indicates that the solvent DMSO was not
able to form adduct with the p53 exon # 5 DNA. Similarly,
no DNA adducts were found using E2 before activation (Fig.
1b). On the other hand, E2-DNA adducts were formed after
E2 activation by DMDO (Fig. 1c). These results are in good
agreement with our earlier observations that E2 requires acti-
vation by epoxidation before it is able to inhibit the DNA-
dependent RNA synthesis [6] and to bind DNA-forming
DNA adducts [13,14]. The important question here is what
is the e¡ect, if any, of these E2-DNA adducts on the replica-
tion of the p53 exon # 5 suppressor gene? For this study, 5 Wg
of the pCRII recombinant DNA containing exon # 5 of the
suppressor gene p53 was reacted with 200 Wg of the DMDO-
activated E2 at room temperature in 33% DMSO (¢nal con-
centration) for either 30 min (30 min group) or 2 h (2 h
group). As a control, 5 Wg of the exon # 5 recombinant
DNA was incubated in 33% DMSO alone for 2 h. DNA
replication was carried out with T7 promoter primer, but in
the absence of ddNTP terminators and 5P-[K-35S]dATP was
used to monitor the synthesis of DNA. After incubation, 1 Wl
aliquots in triplicates of the reaction mixture from each group
were taken for quantitative radioactivity determination using
Fig. 1. 32P-post-labelling evidence for the formation of E2-DNA ad-
ducts after DMDO activation with the cloned exon # 5 of the tu-
mor suppressor gene p53 in vitro. (a) Solvent control group. (b) E2
control group. (c) DMDO-activated E2 group. The conditions for
E2 activation by DMDO and the binding of the activated E2 to
DNA were all the same as described in Table 1, except in the case
when the binding reaction for each group was carried out in the
presence of 33% DMSO for 1 h. 2 Wg of the DNA samples were
used for the 32P-post-labelling experiments. ‘is’ is the internal stand-
ard DNA marker that was included in each sample to monitor the
e⁄ciency of the 32P-post-labelling procedure.
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the TCA washing and GF/C ¢lter counting procedure as de-
scribed previously [19,20]. The results from this study, as
shown in Table 1, indicate that when compared with the con-
trol, the DMDO-activated E2 was able to strongly inhibit the
replication of p53 exon # 5 DNA. The inhibition was 50 and
64% when the plasmid DNA was reacted with DMDO-acti-
vated E2 for 30 min or for 2 h, respectively.
In order to understand the mechanism of this inhibition, an
equal amount (i.e. 0.1 Wg) DNA template in the ¢nal reaction
mixture from each group was used for sequencing gel electro-
phoresis. Fig. 2 shows the results from this study. There are
two points that can be made. (1) The intensity of the radio-
activity labelling bands on the sequencing gel from the
DMDO-activated E2 groups was greatly reduced as compared
with the control group. This con¢rms the fact that less radio-
activity was incorporated into the activated E2 groups as
shown in Table 1. (2) It appears that larger DNA fragments
which are located on the top of the gel preferentially disap-
peared. Instead, many additional faint bands appeared in the
middle or lower portion of the gel. However, because of the
low levels of radioactivity incorporation in the DMDO-acti-
vated E2 groups, the additional faint bands are di⁄cult to see.
For this reason, we decided to run the gel using an equal
amount of radioactivity from each group. The result from
this study is shown in Fig. 3. Again, there are two points
that can be made. (1) Indeed, there are many additional,
although weaker, radioactive bands that can be seen from
both of the 30 min and 2 h groups. These radioactive bands
appeared mostly toward the middle and the lower portion of
the gel and represent smaller pieces of the DNA chain frag-
ments (the arrow on the left of the gel indicates the start of
exon # 5 DNA replication from the 5P-end). These bands are
not from the normal p53 exon # 5 sequencing bands because
the corresponding control lanes do not show these bands. (3)
The larger DNA chain fragments on top of the gel disap-
peared from both 30 min and 2 h groups as a result of the
activated E2 treatment. These results con¢rmed the data ob-
tained in Fig. 2, suggesting that the activated E2 was able to
interfere with the p53 exon # 5 DNA replication producing
smaller sizes of DNA fragments.
Additionally, we believe that the appearance of additional
radioactive bands on the sequencing gel from the activated E2
groups represents errors of incorporation of wrong bases at
the 3P-end of the terminated DNAs. The fact that a DNA
sequencing gel separates DNA fragments is based on the
chain length of the DNA and the sequencing ladder is able
to distinguish two pieces of DNA di¡ering only one base in
length. When one compares the cluster of ‘C’ ladders in the
‘C’ lanes of the control group with the 30 min and 2 h of the
activated E2 groups just above the ‘arrow’ sign from the se-
quencing gel in Fig. 3, it is evident that there have no other
radioactive bands appeared next to the ‘C’ clusters in the
corresponding ‘T’, ‘G’ and ‘A’ lanes of the control group.
On the other hand, one ¢nds that many radioactive bands,
although weaker, appeared in the ‘T’, ‘G’ and ‘A’ lanes from
the 30 min and 2 h activated E2 groups. This result is inter-
preted to mean that the DNA fragments that were terminated
normally with a ‘C’ at the 3P-end of the DNA chain were
replaced with a ‘T’, ‘A’ or ‘G’ base in the activated E2 groups.
Since the DNA sequencing ladders on the sequencing gel rep-
resent the coding strand copied from the template strand of
Table 1
Inhibition of DMDO-activated E2 on the replication of exon 5
DNA of the human tumor suppressor gene p53
Group Cpm/Wg DNA %
Control 169 038 þ 40 888 100
30 min 84 588 þ 11 508 50
2 h 60 807 þ 6 691 36
Values given are means þ S.E.M. of two separate experiments with
six independent determinations.
Fig. 2. E¡ect of DMDO-activated E2 on the replication of exon # 5
of the human tumor suppressor gene p53 by DNA sequencing gel
analysis using equal amounts of DNA template. DMDO-activated
E2 (200 Wg) was reacted with 5 Wg of the pCRII vector containing
exon # 5 DNA as described in Table 1. 0.1 Wg DNA of the ¢nal re-
action mixture from each group was used and analyzed on 8% de-
natured polyacrylamide sequencing gel. After the run, the gel was
vacuum-dried and exposed to the 35U43 Kodak XAR-5 autoradio-
graphic ¢lm, at room temperature for several days before the ¢lm
was developed. The arrow on the left of the gel indicates the start
of exon # 5 DNA replication from the 5P-end.
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the double-stranded DNA, the errors of incorporation of
wrong bases by DNA polymerase are believed to be a result
of the formation of E2-DNA adducts along the clusters of the
complementary ‘G’ bases on the template strand DNA. Fol-
lowing the same reasoning, one ¢nds a similar situation with
the cluster of four ‘T’s, 10 bases above the ‘C’ clusters from
the sequencing gel. In this case, the source of error was be-
lieved to be a result of the presence of E2-DNA adducts from
the complementary four ‘A’ base cluster on the template
strand of DNA. In contrast, the errors of incorporation re-
£ected from the ‘G’ and ‘A’ lanes on the sequencing gel were
hardly detectable, suggesting that either the interaction of the
activated E2 with C and T bases on the template-strand of
DNA was less favorable or the interaction did not result in
frequent errors of incorporation.
Our earlier studies have concluded that E2, after activation
by epoxidation, is able to bind to DNA-forming DNA ad-
ducts both in vitro [10,11] and in vivo [13,14]. However, no
functional tests have been conducted for these E2-DNA ad-
ducts on any of these substrate DNAs. It is known that each
chemical carcinogen has its own DNA base [7^9] and se-
quence [19,20] binding speci¢cities and that the same carcino-
gen-DNA adduct may not have the same biological e¡ect
depending on the base, sequence as well as the conformation
of the DNA where the adducts are formed [20]. Since exon # 5
of p53 has been identi¢ed as one of the mutational hotspots in
breast cancer patients, it is basically important to study the
e¡ect of E2-DNA adducts on the functional role of this im-
portant biological DNA molecule. We believe that the results
from this study are signi¢cant and informative. It is our hope
that this study will lead to further investigations into the mo-
lecular mechanism of E2 as an initiator in carcinogenesis.
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Fig. 3. E¡ect of DMDO-activated E2 on the replication of exon # 5
of the human tumor suppressor gene p53 by DNA sequencing gel
analysis using equal amounts of radioactivity. DMDO-activated E2
(200 Wg) was reacted with 5 Wg of the pCRII vector containing exon
# 5 DNA as described in Table 1. An equal amount of radioactivity
estimated by the ¢lter counting results from each group was applied
onto an 8% denatured polyacrylamide sequencing gel. After the run,
the gel was vacuum-dried and exposed to the 35U43 Kodak XAR-5
autoradiographic ¢lm, at room temperature for several days before
the ¢lm was developed. The arrow on the left of the gel indicates
the start of exon # 5 DNA replication from the 5P-end.
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